Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WP1122 in advanced COVID-19
NCT05365321Phase 2Unknown
- Start
- Dec 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing WP1122 with Placebo (2 arms). Primary endpoint: Area Under the Curve of Interleukin-6 concentrations at Day 10. Status: unknown.
02
Drugs
WP-1122
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05365321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05365321.